CD44 and breast cancer: Furthermore, regardless the proportion of T-ICs in the primary tumors or the breast cancer lines, adriamycin or epriubicin significantly increased the apoptosis of non-CD44+/CD24−cells but not that of CD44+/CD24− cells determined by Annexin V staining (Figure 3C).